Do you have a theory as to why the injectable forms of semaglutide are so popular but the oral formulation has not received as much attention?
2 This study found that GLP-1 receptor agonist use conferred a lower risk of nonexudative AMD compared to insulin after adjusting for follow-up duration using data from an ophthalmic center
The GLP-1 market growth is driven by advancements in drug formulations, particularly the development of oral and long-acting therapies
For example, someone with a fear of germs might wash their hands repeatedly, sometimes even to the point of causing pain or injury to their skin
A subsequent head-to-head trial, SURMOUNT-5, found that Tirzepatide outperformed Semaglutide with an average weight reduction of 20.2 percent compared to 13.7 percent over the same period, marking the first direct clinical comparison between the two leading GLP-1 medications
Kim KH, Son JM, Benayoun BA, Lee C